Investissement Québec, adMare BioInnovations and Jonathan Milner led a $31m round in Epitopea.

Investissement Québec, a provider of a range of financing solutions, adMare BioInnovations, a company dedicated to building the Canadian Life Sciences from sea to sea, and Jonathan Milner led a $31m round in Epitopea with participation from Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, the Harrington Discovery Institute, IRICoR and Novateur Ventures. “In this round we would like to warmly welcome new investors Investissement Québec, adMare BioInnovations and Jonathan Milner, whose participation complements the continued passionate support of our existing transatlantic investor syndicate. This pre-Series A raise provides the necessary finances to accelerate our development campaigns and transition to a clinical-stage company with a focused commitment of delivering our transformational RNA cancer immunotherapy into the clinic in 2026,” Alan C. Rigby, Epitopea CEO.